DIRS.INFO The most relevant business & tech news

☆ Dutch man confirmed as world’s longest-living heart transplant recipient
▼ + stars: | 2024-03-04 | by ( Story Reuters | ) edition.cnn.com time to read: +2 min

He says he is proof that living a long time with a heart transplant is possible. In 1984, the Netherlands had yet to perform its first heart transplant, so cardiologist Albert Mattart referred the teenager to Harefield Hospital in England. Janssen underwent transplant surgery in June that year after a heart became available following a tragic car crash in which two young adults died. The average life expectancy for heart patients after a transplant is 16 years, according to Janssen’s current cardiologist, Casper Eurlings. Transplant patients “need to maintain a healthy lifestyle and be active.

Persons: Bert Janssen, ”, Albert Mattart, Janssen, Piroschka Van De Wouw, Magdi, “, “ I’ve, Casper Eurlings, Harold Sokyrka, ” Eurlings, Yacoub, ” Janssen Organizations: Reuters, Harefield Hospital, Guinness World Records, Guinness . Transplant Locations: Netherlands, England

☆ Clinical data is a goldmine — but Europe's startups are struggling to grow
▼ + stars: | 2023-08-14 | by ( Riddhi Kanetkar | ) www.businessinsider.com time to read: +5 min

Big Pharma and biotech companies often outsource clinical trials to external companies. Europe's early-stage clinical trials startups are flush with funds but they're struggling to grow. The fate — and market cap — of a biotech company often lies with a successful clinical trial. The COVID-19 pandemic also spotlighted another promising alternative to carry out these trials — startups. While the US touts around a dozen clinical trials unicorns valued at $1 billion or higher, per Dealroom estimates, Europe's startups are lagging behind.

Persons: BEN, Janssen, Christoph Ruedig, Maya Zlatanova, Europe hasn't, Matt Wilson, Wilson, Christoph Massner, it's, Ruedig Organizations: Big Pharma, pharma, Janssen Pharmaceuticals, Tempus, Venture, Albion VC, US, Earlybird Ventures Locations: Europe, New York, American

☆ New RSV vaccines may soon put an end to rough seasons
▼ + stars: | 2022-10-31 | by ( Brenda Goodman | ) edition.cnn.com time to read: +15 min

The monoclonal antibody, Synagis, is given monthly during RSV season to protect preemies and other high-risk babies. In the failed RSV vaccine trial, the chemical the researchers used to deactivate the virus denatured its proteins – essentially flattening them. Four companies have RSV vaccines for adults in the final phases of human trials: Pfizer and GSK are testing vaccines for pregnant women as well as seniors. Janssen, Pfizer and GSK each appear effective at preventing infections in adults for the first RSV season after the vaccine. The vaccines for pregnant women are meant to get newborns through their first RSV season.

☆ ЕС проверит вакцину Johnson & Johnson на связь с образованием тромбов
▼ + stars: | 2021-04-10 | by ( Mld Media Srl | ) noi.md time to read: +1 min

Европейское агентство по лекарственным препаратам (EMA) ведет проверку о связи вакцины от коронавируса Janssen с тромбами, говорится на сайте регулятора. Janssen — это вакцина компании Johnson & Johnson, она получила одобрение в Евросоюзе 11 марта. В одном из этих случаев привитый препаратом Janssen скончался. «В настоящее время неясно, существует ли причинно-следственная связь между вакцинацией препаратом Janssen и указанными последствиями», — отметили в регуляторе. Хотя препарат был одобрен в ЕС в марте, внедрение вакцины еще не началось ни в одном государстве-члене союза.

Organizations: Европейское агентство по лекарственным препаратам (), РБК Locations: Евросоюз, США, ЕС

Search resuls for: ". Janssen"

4 mentions found